» Articles » PMID: 36226571

Origin and Timing of De Novo Variants Implicated in Type 2 Von Willebrand Disease

Overview
Journal J Cell Mol Med
Date 2022 Oct 13
PMID 36226571
Authors
Affiliations
Soon will be listed here.
Abstract

Very few studies have shown the real origin and timing of de novo variants (DNV) implicated in von Willebrand disease (VWD). We investigated four families with type 2 VWD. First, we conducted linkage analysis using single nucleotide variant genotyping to recognize the possible provenance of DNV. Second, we performed amplification refractory mutation system-quantitative polymerase chain reaction to confirm the real origin of variant (~0% mutant cells) or presence of a genetic mosaic variant (0%-50% mutant cells) in three embryonic germ layer-derived tissues and sperm cells. Then, three possible timings of DNV were categorized based on the relative likelihood of occurrence according to the number of cell divisions during embryogenesis. Two each with type 2B VWD (proband 1 p.Arg1308Cys, proband 4 p.Arg1306Trp) and type 2A VWD (proband 2 p.Leu1276Arg, proband 3 p.Ser1506Leu) were identified. Variant origins were identified for families 1, 2 and 3 and confirmed to originate from the mother, father and father, respectively. However, the father of family 4 was confirmed to have isolated germline mosaicism with 2.2% mutant sperm cells. Further investigation confirmed the paternal grandfather to be the origin of variant. Thus, we proposed that DNV originating from the two fathers most likely occurred at the single sperm cell, the one originating from the mother occurred at the zygote during the first few cellular divisions; alternatively, in family 4, the DNV most likely occurred at the early postzygotic development in the father. Our findings are essential for understanding genetic pathogenesis and providing accurate genetic counselling.

Citing Articles

Noninversion Variants in Sporadic Hemophilia A Originate Mostly from Females.

Chen M, Shen M, Chang S, Ma G, Lee D, Yan A Int J Mol Sci. 2025; 26(3).

PMID: 39940661 PMC: 11816929. DOI: 10.3390/ijms26030891.


Genotyping R1336X and Eliminating the Pseudogene Amplification in Type 3 von Willebrand Disease Patients.

Khatib M, Bolhassani A, Noormohammadi Z, Ghazizadeh M Indian J Hematol Blood Transfus. 2025; 41(1):121-126.

PMID: 39917504 PMC: 11794745. DOI: 10.1007/s12288-024-01798-8.


De Novo Noninversion Variants Implicated in Sporadic Hemophilia A: A Variant Origin and Timing Study.

Chen M, Shen M, Chang S, Ma G, Lee D, Yan A Int J Mol Sci. 2024; 25(3).

PMID: 38339041 PMC: 10855912. DOI: 10.3390/ijms25031763.


Origin and timing of de novo variants implicated in type 2 von Willebrand disease.

Chen M, Shen M, Chang S, Ma G, Huang Y, Lin C J Cell Mol Med. 2022; 26(21):5403-5413.

PMID: 36226571 PMC: 9639050. DOI: 10.1111/jcmm.17563.

References
1.
Cioppi F, Casamonti E, Krausz C . Age-Dependent De Novo Mutations During Spermatogenesis and Their Consequences. Adv Exp Med Biol. 2019; 1166:29-46. DOI: 10.1007/978-3-030-21664-1_2. View

2.
Daly M, Peake I . A de novo mutation in exon 28 of the von Willebrand factor gene in a patient with type IIA von Willebrand's disease coincides with an MboI polymorphism in the von Willebrand factor pseudogene. Hum Mol Genet. 1993; 2(12):2159-61. DOI: 10.1093/hmg/2.12.2159. View

3.
Shen M, Chen M, Ma G, Chang S, Lin C, Lin B . mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD. Thromb J. 2016; 14(Suppl 1):36. PMC: 5056463. DOI: 10.1186/s12959-016-0092-2. View

4.
Zhang Z, Blomback M, Egberg N, Falk G, Anvret M . Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics. 1994; 21(1):188-93. DOI: 10.1006/geno.1994.1241. View

5.
Ahmad F, Oyen F, Jan R, Budde U, Schneppenheim R, Saxena R . Germline de novo mutations and linkage markers vs. DNA sequencing for carrier detection in von Willebrand disease. Haemophilia. 2014; 20(4):e311-7. DOI: 10.1111/hae.12441. View